JP4486166B2 - 薬物代謝物の定量分析方法及び分析装置 - Google Patents
薬物代謝物の定量分析方法及び分析装置 Download PDFInfo
- Publication number
- JP4486166B2 JP4486166B2 JP2010502364A JP2010502364A JP4486166B2 JP 4486166 B2 JP4486166 B2 JP 4486166B2 JP 2010502364 A JP2010502364 A JP 2010502364A JP 2010502364 A JP2010502364 A JP 2010502364A JP 4486166 B2 JP4486166 B2 JP 4486166B2
- Authority
- JP
- Japan
- Prior art keywords
- metabolite
- mass
- correction coefficient
- intensity
- radioactivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 95
- 238000004445 quantitative analysis Methods 0.000 title claims description 47
- 239000002359 drug metabolite Substances 0.000 title claims description 17
- 239000002207 metabolite Substances 0.000 claims description 232
- 238000012937 correction Methods 0.000 claims description 84
- 150000001875 compounds Chemical class 0.000 claims description 70
- 239000000126 substance Substances 0.000 claims description 66
- 238000005259 measurement Methods 0.000 claims description 61
- 238000004458 analytical method Methods 0.000 claims description 60
- 239000000523 sample Substances 0.000 claims description 57
- 238000004949 mass spectrometry Methods 0.000 claims description 48
- 238000000926 separation method Methods 0.000 claims description 45
- 239000012472 biological sample Substances 0.000 claims description 44
- 238000011002 quantification Methods 0.000 claims description 39
- 241001465754 Metazoa Species 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 20
- 238000011088 calibration curve Methods 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 14
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 10
- 230000002503 metabolic effect Effects 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 238000009781 safety test method Methods 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 claims description 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 85
- 229960005371 tolbutamide Drugs 0.000 description 43
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 239000000047 product Substances 0.000 description 29
- 210000002381 plasma Anatomy 0.000 description 24
- SJRHYONYKZIRPM-UHFFFAOYSA-N 4-hydroxytolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(CO)C=C1 SJRHYONYKZIRPM-UHFFFAOYSA-N 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 210000002700 urine Anatomy 0.000 description 21
- 238000013459 approach Methods 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000012071 phase Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- 229940124530 sulfonamide Drugs 0.000 description 8
- 150000003456 sulfonamides Chemical class 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 210000001589 microsome Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000010833 quantitative mass spectrometry Methods 0.000 description 6
- 238000012916 structural analysis Methods 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- GCMVATDSSHTCOS-UHFFFAOYSA-N Carboxytolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C(O)=O)C=C1 GCMVATDSSHTCOS-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000002552 multiple reaction monitoring Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000002705 metabolomic analysis Methods 0.000 description 4
- 230000001431 metabolomic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010813 internal standard method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000005250 beta ray Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000004460 liquid liquid chromatography Methods 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 238000002541 precursor ion scan Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Computational Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008261999 | 2008-10-08 | ||
| JP2008261999 | 2008-10-08 | ||
| JP2008280004 | 2008-10-30 | ||
| JP2008280004 | 2008-10-30 | ||
| PCT/JP2009/005259 WO2010041459A1 (fr) | 2008-10-08 | 2009-10-08 | Procédé d'analyse quantitative d'un métabolite de médicament et analyseur |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP4486166B2 true JP4486166B2 (ja) | 2010-06-23 |
| JPWO2010041459A1 JPWO2010041459A1 (ja) | 2012-03-08 |
Family
ID=42100420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010502364A Active JP4486166B2 (ja) | 2008-10-08 | 2009-10-08 | 薬物代謝物の定量分析方法及び分析装置 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4486166B2 (fr) |
| WO (1) | WO2010041459A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2976076B1 (fr) * | 2011-05-31 | 2015-02-27 | Imabiotech | Procede de detection et de quantification d'une molecule cible dans un tissu |
| JP5827545B2 (ja) * | 2011-10-28 | 2015-12-02 | 株式会社日立ハイテクノロジーズ | 分析方法および分析装置 |
| JP6288753B2 (ja) * | 2013-05-20 | 2018-03-07 | 花王株式会社 | 多成分試料の質量分析方法 |
| JP6149810B2 (ja) * | 2014-06-13 | 2017-06-21 | 株式会社島津製作所 | 代謝物解析システム及び代謝物解析方法 |
| CN112268961B (zh) * | 2019-07-08 | 2023-06-16 | 中国医学科学院药物研究所 | 一种甾体激素类代谢物的定性和定量分析方法 |
| EP4220152A1 (fr) * | 2020-12-18 | 2023-08-02 | Chugai Seiyaku Kabushiki Kaisha | Procédé de mesure de rapport relatif fu par analyse dynamique |
| CN113702550A (zh) * | 2021-07-27 | 2021-11-26 | 杭州汇健科技有限公司 | 一种代谢谱检测试剂盒及使用方法与应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004028993A (ja) * | 2002-03-14 | 2004-01-29 | Warner Lambert Co Llc | 水素／重水素交換を用いる代謝物のキャラクタリゼーション・システムおよび方法 |
| JP2005098830A (ja) * | 2003-09-25 | 2005-04-14 | Institute Of Physical & Chemical Research | 質量分析法によるタンパク質相互作用物質のスクリーニング方法 |
-
2009
- 2009-10-08 WO PCT/JP2009/005259 patent/WO2010041459A1/fr active Application Filing
- 2009-10-08 JP JP2010502364A patent/JP4486166B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004028993A (ja) * | 2002-03-14 | 2004-01-29 | Warner Lambert Co Llc | 水素／重水素交換を用いる代謝物のキャラクタリゼーション・システムおよび方法 |
| JP2005098830A (ja) * | 2003-09-25 | 2005-04-14 | Institute Of Physical & Chemical Research | 質量分析法によるタンパク質相互作用物質のスクリーニング方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010041459A1 (fr) | 2010-04-15 |
| JPWO2010041459A1 (ja) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McDonald et al. | A comprehensive method for extraction and quantitative analysis of sterols and secosteroids from human plasma | |
| JP4486166B2 (ja) | 薬物代謝物の定量分析方法及び分析装置 | |
| Zhao et al. | Development of high-performance chemical isotope labeling LC–MS for profiling the carbonyl submetabolome | |
| MAuNsELL et al. | Routine isotope-dilution liquid chromatography–tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3 | |
| Cawood et al. | Testosterone measurement by isotope-dilution liquid chromatography–tandem mass spectrometry: validation of a method for routine clinical practice | |
| Vogeser et al. | Liquid chromatography tandem-mass spectrometry (LC-MS/MS)-technique and applications in endocrinology | |
| US20220050090A1 (en) | Mass spectrometry assay method for detection and quantitation of microbiota related metabolites | |
| Liu et al. | The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies | |
| JP2016197110A (ja) | 質量分析によってジヒドロキシビタミンｄ代謝物を検出するための方法 | |
| Mena-Bravo et al. | Two-dimensional liquid chromatography coupled to tandem mass spectrometry for vitamin D metabolite profiling including the C3-epimer-25-monohydroxyvitamin D3 | |
| CN105651901A (zh) | 干血片样品中25羟基维生素d的液相色谱串联质谱检测方法及试剂盒 | |
| Zoppi et al. | Performance evaluation of the new AMS system at Accium BioSciences | |
| Wierzbicka et al. | Determination of alkylresorcinols and their metabolites in biological samples by gas chromatography–mass spectrometry | |
| Chen et al. | Methods used to increase the comprehensive coverage of urinary and plasma metabolomes by MS | |
| Wan et al. | A new sensitive LC/MS/MS analysis of vitamin D metabolites using a click derivatization reagent, 2-nitrosopyridine | |
| Pozo et al. | Detection and characterization of a new metabolite of 17α-methyltestosterone | |
| Wu et al. | An integrated approach for studying exposure, metabolism, and disposition of multiple component herbal medicines using high-resolution mass spectrometry and multiple data processing tools | |
| Kim et al. | Simultaneous analysis of urinary phthalate metabolites of residents in Korea using isotope dilution gas chromatography–mass spectrometry | |
| Minkler et al. | Quantification of carnitine, acetylcarnitine, and total carnitine in tissues by high-performance liquid chromatography: the effect of exercise on carnitine homeostasis in man | |
| CN107436335A (zh) | 一种肉碱类化合物全同位素内标质谱定量方法 | |
| Sobolevsky et al. | Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine | |
| Zhu et al. | Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations | |
| WO2019098179A1 (fr) | Composé marqué par un isotope stable | |
| Zhao et al. | Comparison of LC-MS/MS and EMIT methods for the precise determination of blood sirolimus in children with vascular anomalies | |
| Xue et al. | Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100225 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100325 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4486166 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130402 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140402 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |